France's Equasens Q1 revenue rises on growth across divisions

Equasens SA

29/04/2026 17:12

Overview

France digital healthcare solutions provider's Q1 2026 revenue rose 7.7% yr/yr to €61.4 mln

Growth driven by PHARMAGEST, AXIGATE LINK divisions and EREVO integration

Initial revenue contribution from SÉGUR Wave 2 programme supported results

Outlook

Company to focus on AI integration and SaaS expansion in healthcare solutions in 2026

Equasens to dedicate significant 2026 resources to SÉGUR Wave 2 software qualification

Result Drivers

DIVISION MOMENTUM - PHARMAGEST and AXIGATE LINK divisions saw continued growth, supported by software innovation, hardware expansion and new contracts

EREVO INTEGRATION - Integration of EREVO boosted reported growth in the Medical Solutions division

SÉGUR WAVE 2 - Initial revenue contribution from SÉGUR Wave 2 programme supported results

Company press release: ID:nGNE9QMPqG

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
EUR 61.4 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the it services & consulting peer group is "buy."

Wall Street's median 12-month price target for Equasens SA is €52.00, about 30.5% above its April 28 closing price of €39.85

The stock recently traded at 13 times the next 12-month earnings vs. a P/E of 15 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)